FDA Should Beef Up Post-Market Drug Safety: GAO

Law360, New York (December 9, 2009, 5:45 PM EST) -- The U.S. Food and Drug Administration still has weaknesses in its post-market oversight of drugs, the U.S. Government Accountability Office said Wednesday, three years after finding that the FDA needed to improve its evaluation of drugs after they reach consumers.

The GAO report, issued in response to a request from Sen. Charles Grassley, R-Iowa, is a follow-up to the 2006 report that found the FDA's post-market oversight lacking.

The GAO recommended in 2006 that the FDA clarify the role of its Office of Surveillance and Epidemiology...
To view the full article, register now.